Analystreport

Vascular Biogenics Ltd (NASDAQ: VBLT) had its "buy" rating re-affirmed by analysts at Roth Capital. They now have a $5.00 price target on the stock.

Vascular Biogenics Ltd. - Ordinary Shares  (VBLT) 
Last vascular biogenics ltd. - ordinary shares earnings: 11/14 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: vblrx.com